Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are prevalent in 14 ± 19% of men in their 40s, increasing to 43% in men b 60 y. Symptoms impact on patient's quality of life to varying degrees and more recently have been shown to affect sexual function. A number of questionnaires are available which can assess symptom severity, quality of life and sexual function. Comparative studies in different countries show a similar trend, in that as symptom severity increases, then so does the interference with quality of life, general health status and sexual function. Treatment of LUTS is associated with an improvement in the quality of life of the patient. a 1 -Blockers are an established treatment of LUTS associated with BPH and, in addition, the a 1 -blocker alfuzosin has been shown to improve sexual drive and function. It is not yet known, however, whether this is a direct effect or due to a general improvement in the patient's quality of life. When treating BPH, physicians should be aware of the quality of life aspects to the disease, including sexual function, which is still an important feature in the ageing male.
Evaluation of LUTS
Lower urinary tract symptoms (LUTS) are one of the three components de®ning the disease benign prostatic hyperplasia (BPH) and commonly affect ageing men. They are also the predominant reason why patients present to their primary care physician. In recent years, methods to quantify symptoms reliably and reproducibly have become standardized throughout the world. A number of instruments are available, including the International Prostate Symptom Score (I-PSS), the Danish Prostatic Symptom Score (DAN-PSS) and the International Continence Society BPH Study Group (ICS male) questionnaire. Each of these instruments measures different parameters and are basically aimed at quantifying the degree of symptom severity.
The I-PSS is probably the most commonly used instrument and is recommended by the International Consultation of BPH. 1 It is based on the American Urological Association Symptom Index, 2 which has seven questions relating to LUTS, with the addition of one question on the impact of BPH on quality of life (QOL). The DAN-PSS is a self-administered instrument that is able to measure symptoms as well as associated bother. It includes a total of 12 questions, three of which are related to sexual function. 3, 4 A shortened version is also available, consisting of eight questions on urinary symptoms. 5 Thirty-four questions on severity and associated bother of ®lling and voiding symptoms are assessed in the ICS male questionnaire. 6 As well as assessing individual patients, the I-PSS has been used to measure the prevalence of BPH. Bosch and co-workers 7 used the I-PSS in a community-based study of 502 men aged 55 ± 74 y. Prevalence was recorded using a number of parameters including I-PSS ( b 7 points), prostate volume ( b 30 cm 3 ), maximum¯ow rate (`10 mL/s) and post-void residual urine volume ( b 50 mL). The highest overall prevalence of 19% occurred using the de®nition of BPH that combined a prostate volume of b 30 cm 3 and I-PSS b 7. The prevalence of BPH using the I-PSS has also been recorded in 184 men (20 ± 49 y) of a National Guard Unit in the USA. 8 A total of 15% of men aged in their 40s, the usual age of onset of BPH, 9 had an I-PSS of 8 or greater. In a Scottish community, symptom severity was determined using an adaptation of the Fowler numerical scoring system. 10 The estimated prevalence of BPH in men (n 705) aged 40 ± 79 y was 253 per 1000 men. 11 The prevalence at age 40 ± 49 y was 138 per 1000 men, rising to 430 per 1000 men at age 60 ± 69 y. The presence of the disease was based on prostate size b 20 g in the presence of symptoms of urinary dysfunction and/or a urinary peak¯ow rate`15 mL/s.
Quality of life assessment
Practitioners are becoming increasingly aware that symptoms have varying degrees of`bothersomeness' to their patients, and that as people live longer, their QOL becomes more important to them. Bothersomeness of symptoms can also impact on treatment outcome. In the Veterans Affairs Study, men with severe LUTS were randomized to treatment with transurethral resection of the prostate or watchful waiting. 12 The single most important predictor of failure in the watchful waiting arm was shown to be bothersomeness of symptoms.
Similar methodology to that employed for the development of symptom indices has been applied to measuring bothersomeness of symptoms and overall QOL.
Questionnaires developed to examine QOL associated with BPH vary in their approach and include:
BPH Impact Index Symptom Problem Index Urolife Scale Epstein
The BPH Impact Index (BII) consists of four questions that measure the effect of BPH on various health domains. 13 Summing the responses to these questions provides a total score in the range 0 ± 13, with higher scores indicating a more severe problem. The Symptom Problem Index assesses how troublesome patients ®nd their urinary symptoms. 14 The Urolife Scale originally consisted of 20 questions scored on a 10 cm visual analogue scale. 15 Questions related to physical/functional status and status of mental health, social life and overall health; impact on sexual function was also included. The Urolife Scale has subsequently been modi®ed to a simpler 9-item questionnaire. 16 The questionnaire developed by Epstein and co-workers 17 assesses degree of bother due to urinary symptoms, BPH-speci®c interference with activities of daily living, general physiological well-being and sexual satisfaction.
In addition to measuring symptoms and bother it is important to assess the impact of symptoms on sexual function. Recent studies have consistently highlighted the importance of sexuality in moulding perceptions of QOL in patients with BPH. The French BPH QOL Study Group identi®ed sexuality as one of three signi®cant QOL components. 15 Sexual function and satisfaction with sexual relationships were also two of seven aspects selected from an 89-item questionnaire by patients as being most important in determining QOL. 18 A number of instruments are available, including:
The Brief Sexual Function Inventory (SFI) 19 The International Index of Erectile Function (IIEF) 20 Urolife Scale DANP-SS Of these, the SFI and IIEF have been developed speci®-cally to measure male sexual function. The diversity of QOL questionnaires has led to dif®-culties in comparing ®ndings from different studies. In addition, the impact of BPH on general health status has been largely con®ned to studies of patients attending urology clinics, with only a limited number of community-based population surveys being conducted. A Scottish study involving men registered at two health centres showed that 51% of men with BPH reported interference with at least one of the following activities: drinking before travel or bedtime, driving long distances, sleep, visiting places without a toilet, as well as participation in outdoor sports and social activities. 21 This interference occurred most or all of the time for at least one activity in 17% of men of working age (45 ± 64 y). A more recent report of ®ve year data from the same group of men shows that bothersomeness increased with time as did the level of symptoms. 22 The study also suggested that small increases in symptoms such as dribbling, frequency and nocturia may cause large increases in bothersomeness and that men may exhibit a decreasing tolerance towards these symptoms with time.
QOL score has been shown to be associated with symptom score in a study of 196 men with symptomatic BPH. 23 The strongest correlation found was between urgency (a bothersome symptom) and obstruction, and QOL. In a French questionnaire study of 2000 men, patients with mild, moderate and severe symptoms were asked to express their satisfaction with urinary function. Patients were classi®ed as being`very dissatis®ed',`dissatis®ed',`neutral',`satis®ed', or`very satis®ed'. Results indicated a good correlation between the bothersomeness of symptoms experienced by the patient and symptom score. 24 Comparative studies on the impact of BPH A number of individual studies have highlighted international variations in the prevalence and impact of symptoms of BPH. For example, in a study comparing urinary symptoms in Scottish men aged 40 ± 79 y with those of similar age in Minnesota, USA, the American men reported symptoms that were more frequent, more bothersome and caused greater interference with daily living activities then those of Scottish men. 25 Interestingly, a more recent report by Girman et al. 26 on the impact of LUTS on health related QOL from four countries indicated striking similarities between countries with an ageing population. Data on men from four countries were analysed: US (n 2115; age 40 ± 79 y), France (n 2011; age 50 ± 84 y), Scotland (n 1994; age 40 ± 70 y) and Japan (n 289; age 40 ± 79 y). Each study used different instruments to measure bother, QOL, general overall health and sexual satisfaction. A reverse scale of 0 to 1 was used to combine the results, with 1 being a poor outcome and 0 being excellent health outcome. LUTS was measured by I-PSS in all studies. It was observed that patients with mild symptoms did not appear to be very bothered by their symptoms, but as the severity increased, they become more bothered by symptoms which interfered more with their quality of life, general health status and sexual function (Figure 1 ). These results suggest that increasing severity of LUTS may negatively affect health-related QOL to varying degrees in individual patients. As such, this factor may be useful in patient evaluation. 
Treatment of LUTS
Lukacs and co-workers 27 have examined the effect of treating LUTS on a patient's QOL, including sexual drive. A total of 3228 patients with BPH were included in a prospective three-year open-label study and treated with alfuzosin 2.5 mg three times daily (tid). Symptoms were assessed using the modi®ed Boyarsky questionnaire and QOL using the Urolife TM BPH QoL 20 at baseline, 3, 6, 12, 18, 24, 30 and 36 months. Results indicated that symptoms score was signi®cantly (P 0.0001) reduced by 54% at three months and that this was maintained for the duration of the study (Figure 2 ). Importantly, this was associated with a signi®cant (P`0.0001) improvement in health related QOL score; the onset of maximum improvement was at 12 months and this was maintained up to three years.
a-Blockers and sexual function
Recent data suggest that a-blockade may be both an erection promoter and an erection facilitator. It is known that trabecular smooth muscle of the corpus cavernosum has both a 1 and a 2 receptors, with a 1 probably predominating. Phentolamine, a non-selective a-antagonist, can promote erections. Dose-dependent negative ejaculatory effects have been observed with the a-blocker tamsulosin. A 53-week controlled study conducted in the US showed that 10% and 26% of patients had abnormal ejaculations when treated with tamsulosin, 0.4 mg/day and 0.8 mg/ day, respectively, compared with none of the placebo group. 28 It is not clear whether these effects are due to actions on the prostate or bladder neck. The possibility remains that a vasal effect is present. A study that attempted to improve the understanding of the relationship between urinary symptoms and sexual function was conducted in 2829 patients with BPH treated with alfuzosin 2.5 mg tid or 5 mg bid for one year in a primary care setting. 29 The Urolife TM BPH QoL 9 was used to assess sex drive, erections and overall sexual satisfaction. Response was measured using a visual analogue scale, the maximum score being 30 ( Figure 3 ). Data were analysed according to patient age and symptom severity. Baseline patient characteristics are shown in Table 1 .
Mean age was 66 y and mean I-PSS was 19.5. The majority of patients had moderate to severe symptoms; the relative percentages of each symptom category were: mild (I-PSS 7) 2%; moderate (I-PSS 8 ± 19) 49%; and severe (I-PSS 20) 49%. At baseline, sex drive and function decreased with age and increasing symptom severity. Following treatment with alfuzosin, particularly in the younger age group, there was an appreciable improvement in overall sex life (Figure 4) . This demands the question as to whether a-blockers have a central or peripheral effect on sexual function, and whether they are acting as promoters, facilitators, or both. It should also be considered that by improving a patient's symptoms, ablockers are bringing about a general improvement in the patient's well-being and consequently an improvement in his sex drive.
A second study, the ALFIN Study, as well as comparing the ef®cacy of alfuzosin and ®nasteride and their combination in BPH, also examined the effect of these therapies on erection and ejaculation using the DAN-PSS questionnaire. 30 Baseline responses to the questions: (1) Can you get an erection? and (2) Do you have ejaculations? are shown in Figure 5a and b. As expected in this older group of patients, a large percentage of patients did not get good erections. The majority of men aged`65 y had normal ejaculation volumes, but this decreased with age. The effect of therapy on erectile function is shown in Figure 6 . As can be seen, alfuzosin had very little effect on the ability to achieve an erection, whereas erectile func- Figure 3 The Urolife TM BPH QoL 9 visual analogue scales. tion decreased with ®nasteride therapy and with the combination of the two drugs, presumably due to the contribution of ®nasteride. With regard to ejaculation abnormalities, again, alfuzosin had no effect compared with ®nasteride therapy (Figure 7 ).
Conclusion
It has been shown that symptom evaluation is critical in both the diagnosis of BPH and in treatment evaluation. Equally important are QOL aspects to the disease and the patients' perspective of his disease has to be fully recognized by urologists. Sexual function is also a critical component of older life and perhaps BPH speci®cally. Clearly, men are concerned about this aspect of their life and particularly if any treatment for BPH they undergo will have an adverse effect. Varying degrees of erectile function exist in men with BPH and urologists need to carefully judge which treatment to recommend in order not to tip the balance towards erectile dysfunction. 
